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Abstract (150/150 words) 
The diagnosis of clinical antibody mediated rejection (AMR) in lung transplantation is 
based on allograft dysfunction, donor-specific antibodies (DSA) and histopathological 
findings, but its management remains poorly defined. A 48-year-old female received 
bilateral lung transplantation, with low-titer preformed class II DSA and a negative 
flow-cytometry crossmatch at transplant. After an uneventful early post-transplant 
course, she developed at day 7 rapidly progressive dyspnea, high-titers class I and II 
DSA, de novo positive T and B cell crossmatches with capillary C4d deposits on 
transbronchial lung biopsy. She was successfully treated with one 600mg dose of 
eculizumab, three weekly high-dose intravenous immunoglobulins followed by one 
dose of rituximab at 1 month post-transplantation, without the need for 
plasmapheresis or T cell depleting agents, resulting in a rapid reversal of the acute 
AMR episode. In conclusion, this therapeutic approach should be considered and 
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Introduction 
Mounting evidence exists on the risk of antibody mediated rejection (AMR) after lung 
transplantation {Roux et al., 2016, Am J Transplant, 16, 1216-28} {Snyder et al., 2013, 
Chest, 144, 226-233}. In 2016, the International Society for Heart and Lung 
Transplantation (ISHLT) established for the first time a consensus report which 
defines and stages clinical and subclinical AMR (acute or subacute) based on the 
presence of donor specific-antibodies (DSA), specific histopathologic features 
including neutrophil margination and neutrophil capillaritis and arteritis, capillary C4d 
deposition and exclusion of other differential diagnoses {Levine et al., 2016, J Heart 
Lung Transplant, 35, 397-406}. The optimal management of acute AMR remains 
poorly defined, and is mostly based on previous experience derived from kidney 
transplantation with plasmapheresis (+/- eculizumab), intravenous high-dose 
Immunoglobulins (IVIG) and rituximab administration {Chehade et al., 2015, 
Pediatrics, 135, e551-5} {Chehade and Pascual, 2016, Transplantation, 100, 264-5}. 
  
Case presentation  
A 48-year-old female received bilateral lung transplantation because of 
lymphangioleiomyomatosis with severe obstructive syndrome. Prior to transplantation, 
she had only one detectable (>500 mean fluorescence intensity (MFI)) low-titer 
preformed class II DSA (HLA DR17: MFI 1783) by Luminex (Austin, TX), but with a 
negative flow-cytometry crossmatch. Standard immunosuppressive induction therapy 
(two 20mg doses of basiliximab at day 0 and 4) was used. After an uneventful early 
post-transplant course, she developed at day 7 rapidly progressive dyspnea with 
hypoxemia (Figure 1A-B). The chest X-ray showed new bilateral interstitial 
pulmonary infiltrates.  Repeat Luminex-assay on post-operative day (POD) 7, 9 and 
13 revealed increase of class-I (anti-HLA A24 and B8) and class II (anti-HLA DR17 
and DQ2) DSA with de novo positive flow-cytometry T and B crossmatches (Figure 
1C-D). A transbronchial lung biopsy was performed on POD 13 which showed linear 
C4d endothelial deposits with minor peri-capillary mononuclear infiltrates and 
scattered neutrophils (Figure 1E-H). C5b-C9 staining was negative.  She was treated 
on POD 8 with a single 600mg dose of eculizumab preceded with 250mg intravenous 
methylprednisolone, followed by 3 weekly high-dose IVIG (2g/kg), and on POD28 
with one dose of rituximab (375 mg/m2). Terminal complement blockade (> 97% 
inhibition) within 48h after eculizumab administration was demonstrated by functional 
analysis of the complement cascade (classical pathway, alternative pathway and 
lectin pathway of complement activation). Oxygen requirements rapidly decreased 
within 24hours after eculizumab administration and she was off oxygen-therapy by 
day 14 post transplantation (Figure 1A). Circulating DSA progressively decreased 
below 2000 MFI by POD 41, and remained under 2000 MFI thereafter (Figure 1C). 
Peripheral B cells are still depleted three years after rituximab administration (<10 B 
cells/μl). Control transbronchial biopsy at 18 months’ post-transplantation did not 
reveal any residual or active immuno-histological signs for AMR (C4d negative). The 
patient is currently doing well with a three-year follow-up and without any evidence 
for chronic lung allograft dysfunction (CLAD).  
 
Discussion 
This case illustrates that acute AMR can develop early after lung transplantation in a 
sensitized recipient who had low-titer preformed DSA prior to transplantation. 
Importantly, no hyperacute AMR occurred in this patient. These results highlight the 
importance to closely monitor DSA and cross-matches in such patients post-
transplantation. Interestingly, recent data indicate that de novo DSA appearing within 
the first 30 days post-transplantation are associated with significantly worse long-
term clinical outcomes {Le Pavec et al., 2016, J Heart Lung Transplant, 35, 1067-77}. 
Moreover, C1q binding and detection of intragraft DSA may be additional useful tools 
for the diagnosis of AMR, as recently suggested by a retrospective analysis of 51 
lung-transplant recipients {Visentin et al., 2016, J Heart Lung Transplant, 35, 1418-
1426}.  
 
Eculizumab administration rapidly reversed clinical early acute AMR after lung 
transplantation, without the need for T-cell depleting agents (e.g thymoglobulin) or 
plasmapheresis. Histopathological findings from the lung biopsy, performed 5 days 
after eculizumab, suggested that blockade of the terminal complement pathway could 
neutralize the consequences of pathogenic DSA (i.e C5b-C9 deposits were not 
detected), but as expected C5 blockade did not inhibit complement classical pathway 
activation as shown by the presence of capillary C4d deposits on lung’s biopsy, 
similar to the report by Stegall et al. in kidney transplantation {Stegall et al., 2011, Am 
J Transplant, 11, 2405-13}. It should be emphasized that, until recently, the treatment 
of severe acute AMR has been based on immediate removal of DSA by 
plasmapheresis and on B cells immuno-modulation by IVIG, rituximab or bortozemib 
therapy {Moll and Pascual, 2005, Am J Transplant, 5, 2611-8} {Chehade and Pascual, 
2016, Transplantation, 100, 264-5} {Hachem et al., 2010, J Heart Lung Transplant, 
29, 973-80}. Thus, in our case, administration of high-dose IVIG and rituximab, 
associated with increased baseline maintenance immunosuppression, were likely 
critical in the overall successful management and resolution of the acute AMR 
episode. Interestingly, anti T-cell therapy was not necessary, probably because the 
rejection process was predominantly humoral and not cellular in its mechanism 
effector. Finally, the cost-effectiveness of eculizumab as compared to conventional 
plasmapheresis {Ius et al., 2015, J Heart Lung Transplant, 34, 50-8} still warrants 
prospective studies based on a multicentric approach due to the low incidence of 
reported clinical acute AMR.  
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(A)  Oxygen maximal flow rate over time. Treatment with eculizumab (600 mg) on 
post-operative day (POD) 8, 3 weekly high-dose intravenous immunoglobulins 
(2g/kg)) and rituximab (375 mg/m2) on POD 28. (B) Chest X-ray at post-operative day 
(POD) 4 and 9. (C) Donor specific class I and class II antibodies over time. (D) Flow 
cytometry crossmatches gated on viable (propidium iodide negative) donor CD3 or 
CD19 cells on POD 0, 7 and 9. Negative control (NC) are third party serum controlled 
for anti-HLA antibodies co-cultured with donor cells. Lung biopsy performed on POD 
13 showing CD3 staining (E, magnification x20), hematoxylin-eosin coloration (F, 
magnification x40), C4d immunofluorescence on frozen section (G, magnification 
x40), C4d immunohistochemistry on paraffin section (H, magnification x40). Arrows 
show C4d deposits on the pulmonary capillaries. Abbreviation: negative control (NC); 
Day (D); intensive care unit (ICU); intravenous immunoglobulins (IVIG). 
